Co-Authors
This is a "connection" page, showing publications co-authored by Matteo Bassetti and Oliver Cornely.
Connection Strength
2.181
-
What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. J Antimicrob Chemother. 2018 01 01; 73(suppl_1):i14-i25.
Score: 0.749
-
Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Med. 2017 Sep; 43(9):1225-1238.
Score: 0.706
-
Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project. Mycoses. 2019 Apr; 62(4):310-319.
Score: 0.201
-
Isavuconazole shortens the QTc interval. Mycoses. 2018 Apr; 61(4):256-260.
Score: 0.187
-
Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect. 2021 Aug 26.
Score: 0.060
-
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Med. 2021 08; 47(8):819-834.
Score: 0.060
-
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021 06; 21(6):e149-e162.
Score: 0.057
-
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 2020 Aug; 46(8):1524-1535.
Score: 0.056
-
Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbe. 2020 Jun; 1(2):e53-e55.
Score: 0.055
-
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther. 2018 Dec; 7(4):439-455.
Score: 0.049